Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of HS-10506 in Chinese adults with insomnia disorder
CTR20261617Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HS-10506 in Insomnia, sponsored by Hengrui Therapeutics. Started Apr 2026; status: active.
02
Drugs
HS-10506
03
Conditions
Insomnia
Beyond the preview
Go deeper on CTR20261617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261617.